MRK Stock Recent News
MRK LATEST HEADLINES
Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.
In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.
Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Keytruda has been a major revenue driver for MRK, with continued sales growth and potential for extended patent protection through a subcutaneous version. It pays a well-covered dividend based on next year's expected EPS and has a strong balance sheet even after making a multi-billion dollar collaboration payment.
Merck has managed to thrive throughout its 132-year corporate history. The company posted healthy sales and non-GAAP EPS growth in the third quarter. Merck boasts an A+ credit rating from S&P on a stable outlook.
Merck & Co. is a drug manufacturer that has outperformed the healthcare ETF and the S&P 500 over the past decade. The company's pharmaceutical segment, including products like Keytruda and vaccines, contributes significantly to its revenue. MRK has a strong dividend scorecard, with consistent dividend growth, a high yield, and a healthy payout ratio.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
The U.S. Food and Drug Administration (FDA) has declined to approve Merck's drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.
Consider These 3 SWAN Stocks To Collect Dividends Almost Monthly
Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.